



# SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

**Ref:** SPL/BSE/CORP-SEC/2021-22/74

**Dated:21.07.2021**

**To,**

The Deputy Manager (Corporate Services)  
The Bombay Stock Exchange Limited  
1<sup>st</sup> Floor, Rotunda Bldg  
B.S Marg , Fort  
Mumbai -400001

Sub: Reconciliation of Share Capital Audit Report Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended 30<sup>th</sup> June 2021.

Sir,

We are sending herewith Reconciliation of Share Capital Audit Report as per the Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended on 30<sup>th</sup> June 2021.

Kindly take note of the same

For Sandu Pharmaceuticals Limited



PRATIKA MHAMBRA  
Company Secretary

# ND & ASSOCIATES

Practising Company Secretaries

*Neeta H. Desai*

BA, LLB, LLM, FCS  
Tel : 02224095104  
Mobile: 09821498216  
Mobile: 09892288254



279/18 Shantikunj, Road No. 31  
Sion East, Mumbai – 400022  
E-mail: [ndassociates2128@gmail.com](mailto:ndassociates2128@gmail.com)  
E-mail: [ndassociates@rediffmail.com](mailto:ndassociates@rediffmail.com)

## RECONCILIATION OF SHARE CAPITAL AUDIT

(As per regulation 76 of the SEBI (Depositories and Participants) Regulation, 2018)

1	For Quarter Ended	30 <sup>th</sup> June 2021	
2	ISIN :	INE 751D01014	
3	Face Value :	Rs. 10/- each	
4	Name of the Company	Sandu Pharmaceuticals Limited.	
5	Registered Office Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511	
6	Correspondence Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511	
7	Telephone & Fax No.	Tel:0832-2407473/74 Fax:0832-2407008	
8	Email address	corp.sec@sandu.in	
9	Names of the Stock Exchanges where the company's securities are listed:	Mumbai Stock Exchange	
10	Issued Capital	Number of Shares	% of Total Issued Capital
11	Listed Capital (Exchange wise) (as per company records)	7920997	-----
		BSE: 7081000	-----
		<b>30.06.2021</b>	<b>%</b>
12	Held in dematerialized form in NSDL	4562895	64.44
13	Held in dematerialized form in CDSL	1596355	22.54
14	Physical	921750	13.02
15	Total No. of shares (12+13+14)	<b>7081000</b>	<b>100 %</b>
16	Reasons for difference if any, between (10&11), (10&15), (11&15):		<b>Yes</b>
17	Certifying the details of changes in share capital during the quarter under consideration as per Table below:		<b>N.A</b>

Particulars	No of shares/warrants	Applied / Not applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin.appr. pending for SE Specify Names)
Convertible Warrants	25,79,990	Applied	BSE	No	No	Received
Equity Shares on Conversion of warrants	8,39,997	Applied	BSE	No	No	BSE

\* Rights, Bonus, Preferential issue, ESOPs/ Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18	Register of Members is updated (Yes / No) If not, updated up to which date	Yes -----
19	Reference of previous quarter with regards to excess Dematerialized shares, if any.	N. A
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason for delay:	N. A
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :	

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days	---	---	---
Pending for more than 21 days	---	---	---

22	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mrs. Pratika P. Mhambray (Company Secretary & Compliance Officer) Tel:0832-2407473/74 Fax:0832-2407008
23	Name, Address, Tel. & Fax No., Regn. No. of the Auditor	Neeta H. Desai 279/18, Shantikunj, Sion (E), Road No. 31, Mumbai – 400 022. C. P. No. 4741, Tel: 24095104
24	Appointment of common agency for share registry work (if yes (name & address))	Link Intime India Private Ltd C-101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400083
25	Any other detail that the auditor may like to provide	The Company issued 25,79,990 Convertible Warrants and received in principle approval no. DCS/PREF/BA/PRE/1120/2020-21 dated 25.03.2021 from BSE. The Said warrants were allotted on 30.03.2021. On 31.03.2021 - 8,39,997 equity shares were allotted on conversion of warrants. The Company has applied for listing approval for the same. The above certificate is issued based on the electronic data provided by the Company. The physical verification of the records was not possible due to COVID-19 Pandemic.

**Note:**

The above certificate is issued based on the Register of Members, beneficiary details and other documents furnished by the Company and its Share Transfer Agents M/s. Link Intime India Private Limited and also the explanation given to us.

**Place: Mumbai****Date: 14.07.2021****UDIN: F003262C000631846****For ND & Associates**

NEETA  
HARKISHAN  
DESAI

Digitally signed by NEETA HARKISHAN DESAI  
DN: cn=Neeta Harkishan Desai, o=Sandu Pharmaceuticals Limited, email=neeta@sandupharma.com, c=IN  
Date: 2021.07.14 15:51:50 +05'30'

**Neeta H. Desai**  
**Company Secretary**  
**C P No. 4741**